Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria
Status:
Withdrawn
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with
PD-1 antibody compared with transarterial chemoembolization (TACE) for patients with
intermediate-stage hepatocellular carcinoma (HCC) beyond up-to-seven criteria
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Guangzhou No.12 People's Hospital Kaiping Central Hospital